These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12075859)

  • 21. Transcranial sonography of the substantia nigra: digital image analysis.
    Skoloudík D; Jelínková M; Blahuta J; Cermák P; Soukup T; Bártová P; Langová K; Herzig R
    AJNR Am J Neuroradiol; 2014 Dec; 35(12):2273-8. PubMed ID: 25059698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disease with and without preceding essential tremor-similar phenotypes: a pilot study.
    Wurster I; Abaza A; Brockmann K; Liepelt-Scarfone I; Berg D
    J Neurol; 2014 May; 261(5):884-8. PubMed ID: 24590404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.
    Rhodes SL; Buchanan DD; Ahmed I; Taylor KD; Loriot MA; Sinsheimer JS; Bronstein JM; Elbaz A; Mellick GD; Rotter JI; Ritz B
    Neurobiol Dis; 2014 Feb; 62():172-8. PubMed ID: 24121126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study.
    Schroeder U; Behnke S; Buchholz HG; Fassbender K; Schreckenberger M; Berg D
    J Neurol; 2013 Jul; 260(7):1907-11. PubMed ID: 23564333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients.
    Bouwmans AE; Vlaar AM; Mess WH; Kessels A; Weber WE
    BMJ Open; 2013; 3(4):. PubMed ID: 23550093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control.
    Shin HY; Joo EY; Kim ST; Dhong HJ; Cho JW
    Neurol Sci; 2013 Jun; 34(6):935-40. PubMed ID: 22843227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcranial sonography in pantothenate kinase-associated neurodegeneration.
    Kostić VS; Svetel M; Mijajlović M; Pavlović A; Ječmenica-Lukić M; Kozić D
    J Neurol; 2012 May; 259(5):959-64. PubMed ID: 22057405
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study.
    Martínez-Hernández R; Montes S; Higuera-Calleja J; Yescas P; Boll MC; Diaz-Ruiz A; Rios C
    Neurochem Res; 2011 Nov; 36(11):2111-5. PubMed ID: 21706376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.
    Berg D
    J Neural Transm (Vienna); 2011 Apr; 118(4):613-9. PubMed ID: 21207077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.
    Walter U
    J Neural Transm (Vienna); 2011 Apr; 118(4):607-12. PubMed ID: 21190047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease.
    Berg D
    J Neural Transm (Vienna); 2011 Mar; 118(3):453-61. PubMed ID: 20830493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sonography of the parenchyma in Parkinson's disease].
    Hagenah J; Seidel G
    Nervenarzt; 2010 Oct; 81(10):1189-95. PubMed ID: 20802993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcranial sonography for diagnosis of Parkinson's disease.
    Mehnert S; Reuter I; Schepp K; Maaser P; Stolz E; Kaps M
    BMC Neurol; 2010 Jan; 10():9. PubMed ID: 20089201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodromal non-motor symptoms of Parkinson's disease.
    Pellicano C; Benincasa D; Pisani V; Buttarelli FR; Giovannelli M; Pontieri FE
    Neuropsychiatr Dis Treat; 2007 Feb; 3(1):145-52. PubMed ID: 19300544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcranial duplex in the differential diagnosis of parkinsonian syndromes: a systematic review.
    Vlaar AM; Bouwmans A; Mess WH; Tromp SC; Weber WE
    J Neurol; 2009 Apr; 256(4):530-8. PubMed ID: 19224315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics of iron regulation and the possible role of iron in Parkinson's disease.
    Rhodes SL; Ritz B
    Neurobiol Dis; 2008 Nov; 32(2):183-95. PubMed ID: 18675357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Iron contributes to the formation of catechol isoquinolines and oxidative toxicity induced by overdose dopamine in dopaminergic SH-SY5Y cells.
    Wang R; Qing H; Liu XQ; Zheng XL; Deng YL
    Neurosci Bull; 2008 Jun; 24(3):125-32. PubMed ID: 18500384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms.
    Berg D
    Neurochem Res; 2007 Oct; 32(10):1646-54. PubMed ID: 17468954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity.
    Schweitzer KJ; Behnke S; Liepelt I; Wolf B; Grosser C; Godau J; Gaenslen A; Bruessel T; Wendt A; Abel F; Müller A; Gasser T; Berg D
    J Neural Transm (Vienna); 2007 Sep; 114(9):1167-71. PubMed ID: 17446999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism.
    Tsai CF; Wu RM; Huang YW; Chen LL; Yip PK; Jeng JS
    J Neurol; 2007 Apr; 254(4):501-7. PubMed ID: 17401518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.